AI Pharma Acquirers Wave
Alex Mooney@alex_mooney
+1.3%
since Oct 6
The idea
I believe AI is about to collapse the cost and time of drug discovery, and the winners will be big pharma companies with the balance sheets to adopt these tools or simply buy the AI-native labs outright. This starts with US pharma giants, spreads to rich aging nations like Switzerland, Japan and Denmark, with a small slice in likely acquisition targets and the data and trials infrastructure AI pipelines depend on. I'm holding cash back to add on dips since this is catalyst-driven and will swing, and I'm watching whether Oura's shelved IPO revives as a signal the wave is turning real.
What it owns
- American pharmaceutical companies with deep balance sheets and active artificial intelligence discovery programs positioned to capture early gains from AI-accelerated drug development. · Eli LillyIt has the largest balance sheet and most visible AI drug-discovery programs among American acquirers, making it the first place gains appear if AI accelerates drug development., Merck & Co.It has repeatedly partnered and acquired its way into AI discovery, converting those deals into pipeline candidates across its drug business., AbbVieIt grows through acquisition and maintains the balance sheet to buy AI-native labs outright while converting those purchases into discovery engines., Johnson & JohnsonIt anchors the American acquirer bucket with the steadiest balance sheet in pharmaceutical research while adopting AI across drug discovery operations., Bristol-Myers SquibbIt faces patent cliffs on existing drugs and uses AI-driven discovery as the fastest route to rebuild its pipeline with new candidates., PfizerIt offers large-scale balance sheet exposure to an acquirer under pressure to rebuild its pipeline through AI-native lab purchases., AmgenIt applies AI to biologics, one of the hardest and most valuable drug discovery areas where a real speedup from artificial intelligence delivers disproportionate returns., Gilead SciencesIt generates cash to fund acquisitions and has a track record of buying growth, making it a natural bidder for AI-native drug discovery labs.47%
- Drugmakers from wealthy countries with aging populations that adopt AI discovery programs as the technology wave spreads beyond the United States. · NovartisIt runs AI discovery partnerships as a major Swiss drugmaker positioned to benefit as the boom spreads to wealthy aging nations beyond America., AstraZenecaIt maintains one of the broadest pipelines outside the United States and has adopted AI discovery early, catching the wave as it spreads internationally., SanofiIt has publicly committed to being an AI-first drugmaker and shows the clearest adoption story among large foreign pharmaceutical companies., Novo NordiskIt generates the cash flow to fund AI adoption and acquisitions as the boom spreads to wealthy aging nations with high research budgets., Takeda PharmaceuticalIt is Japan's largest drugmaker serving the world's oldest wealthy population, positioned to benefit from rising medical demand met through AI-accelerated drug discovery.21%
- AI-native drug discovery companies and data platforms attractively priced for acquisition by larger pharmaceutical companies seeking to build or accelerate their artificial intelligence capabilities. · SchrödingerIt sells simulation software that big pharmaceutical companies use to design molecules computationally, functioning as both a discovery tool and a plausible acquisition target., Tempus AIIt owns patient data that AI drug discovery requires, making it valuable independently and attractive to pharmaceutical acquirers seeking to build discovery capability., Recursion PharmaceuticalsIt represents one of the purest AI-native drug discovery platforms that larger pharmaceutical companies would acquire at a premium to accelerate their own pipelines.9%
- Companies providing the infrastructure, services and equipment that every AI-discovered drug requires to move through human trials and reach approval. · Thermo Fisher ScientificIt supplies the laboratory equipment and services underlying drug discovery globally, benefiting from rising research spending across pharmaceutical companies regardless of outcome., IQVIA HoldingsIt runs more human clinical trials than any competitor, capturing value if AI-flooded pipelines require increased trial volume and capacity.8%
- Other · DNA3%
- Cash12%